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Activating  Fc    receptors  (FcRs)  stimulate 
immune  cell  effector  mechanisms,  such  as   
antibody-dependent cell-mediated cytotoxicity 
(ADCC) and phagocytosis (ADCP), which com-
bine to facilitate antibody-mediated tumor cell 
killing (Nimmerjahn and Ravetch, 2008; Hogarth 
and Pietersz, 2012). The importance of FcR-
mediated  immune  effector  cell  function  has 
been demonstrated in preclinical efficacy stud-
ies for antibodies targeting a range of tumor 
cell–expressed receptors, including trastuzumab 
(HER2) and rituximab (CD20; Clynes et al., 
2000; Nimmerjahn and Ravetch, 2012). The in-
hibitory FcR, FcRIIB, functions to modulate 
activating FcR-mediated effector mechanisms 
in immune cells that coexpress both FcR classes, 
such as macrophages and dendritic cells. FcRIIB 
has recently been implicated in augmenting 
antibody-mediated receptor forward signaling 
through a mechanism of cross-linking in target 
cells expressing the TNF receptor (TNFR) fam-
ily members TNFRSF10, TNFRSF10B (DR4 
and DR5, respectively), and TNFRSF5 (CD40; 
Wilson et al., 2011; Li and Ravetch, 2012).   
It remains unclear what contribution FcR 
biology has in the modality of antibody thera-
peutics that target other cell surface receptors. 
In particular, the emerging clinical benefit of ago-
nistic antibodies targeting the T cell–APC inter-
face raises the possibility that FcR coengagement 
may contribute to their in vivo mechanism of 
action (Mellman et al., 2011).
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Fc  receptor (FcR) coengagement can facilitate antibody-mediated receptor activation in 
target cells. In particular, agonistic antibodies that target tumor necrosis factor receptor 
(TNFR) family members have shown dependence on expression of the inhibitory FcR, 
FcRIIB. It remains unclear if engagement of FcRIIB also extends to the activities of 
antibodies targeting immunoregulatory TNFRs expressed by T cells. We have explored the 
requirement for activating and inhibitory FcRs for the antitumor effects of antibodies 
targeting the TNFR glucocorticoid-induced TNFR-related protein (GITR; TNFRSF18; CD357) 
expressed on activated and regulatory T cells (T reg cells). We found that although FcRIIB 
was dispensable for the in vivo efficacy of anti-GITR antibodies, in contrast, activating 
FcRs were essential. Surprisingly, the dependence on activating FcRs extended to an 
antibody targeting the non-TNFR receptor CTLA-4 (CD152) that acts as a negative regula-
tor of T cell immunity. We define a common mechanism that correlated with tumor effi-
cacy, whereby antibodies that coengaged activating FcRs expressed by tumor-associated 
leukocytes facilitated the selective elimination of intratumoral T cell populations, particu-
larly T reg cells. These findings may have broad implications for antibody engineering 
efforts aimed at enhancing the therapeutic activity of immunomodulatory antibodies.
© 2013 Bulliard et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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and cytokine production in vitro (Fig. 2 D and not depicted). 
Both DTA-1 rIgG2b and mIgG2a showed potent antitumor 
efficacy, which was abrogated in absence of activating FcRs 
but was not impacted by the absence of FcRIIB expression 
(Fig. 1 and Fig. 2 E). Eliminating FcR interaction through 
the N297A mutation abrogated the antitumor activity of DTA-1 
(Fig. 2 F). The three versions of DTA-1 showed similar GITR 
saturation properties in the tumor and draining lymph, support-
ing common pharmacokinetic/pharmacodynamic properties 
Preclinical studies in mice using agonistic antibodies 
targeted  to  glucocorticoid-induced TNFR-related  protein 
(GITR)—a costimulatory TNFR expressed by regulatory and 
activated T cells—have shown compelling antitumor activity 
in syngeneic mouse tumor models (Turk et al., 2004; Ko et al., 
2005). In vitro, stimulation of GITR with agonist antibodies 
can induce forward signaling into T cells, which promotes 
proliferation and cytokine production (Kanamaru et al., 2004; 
Ronchetti et al., 2007). In vivo, several mechanisms have been 
proposed to contribute to the antitumor activity of antibodies 
targeting  GITR;  however,  the  current  paradigm  stipulates 
that agonist properties of these antibodies promotes cytotoxic 
effector T cell generation, while dampening the immunosup-
pressive effects by FoxP3+ CD4+ T reg cells (Ronchetti et al., 
2012; Schaer et al., 2012). The recent findings that antibodies 
targeted to TNFR family members require FcRIIB inter-
action for their in vivo activities led us to explore a common 
mechanism  for  antibodies  targeting TNFRs  expressed  by   
T cells, using GITR to test this paradigm.
RESULTS AND DISCUSSION
Activating, but not inhibitory, FcRs are necessary  
for antitumor activity of a GITR-targeting antibody
To evaluate the contribution of activating or inhibitory FcRs 
in the mechanism of tumoricidal activity of an agonist anti-
body targeting GITR (clone DTA-1, rat IgG2b), Colon26 
colorectal  cancer  cells  were  implanted  subcutaneously  in 
wild-type, FcRIIB-, or Fc common  chain–deficient mice. 
The common  chain cofactor is required for assembly and 
membrane expression of the activating FcRs I, III, and IV 
(Nimmerjahn and Ravetch, 2008). Mice with preformed tu-
mors (70 mm3) were treated with a single dose of the anti-
GITR antibody (clone DTA-1) or a rat IgG2b isotype control. 
As previously shown for this tumor model, DTA-1–mediated 
single dose regressions in 100% of wild-type mice (Fig. 1 A; 
Zhou et al., 2007). In contrast to recent reports studying 
anti-TNFR antibodies targeting DR4, DR5, or CD40, the 
antitumor efficacy of DTA-1 was independent of FcRIIB 
expression (Fig. 1 B; Wilson et al., 2011; Li and Ravetch, 
2012). Instead, activating FcRs were required for the tumori-
cidal activity of a GITR-targeting antibody (Fig. 1 C).
Co-engagement of FcRs by DTA-1 is required  
for optimal antitumor activity
To further examine the contribution of activating FcRs for 
the tumoricidal activity of antibodies to GITR, we generated 
two chimeric antibodies from the parental DTA-1 rat IgG2b: 
a murine IgG2a (mIgG2a), and mIgG2a with a N297A muta-
tion that eliminates binding to all murine FcRs (not depicted; 
Shields et al., 2001; Chao et al., 2009; Wilson et al., 2011). 
Binding to in vitro–stimulated splenic T cells was conserved 
for the murine IgG2a DTA-1 variants and was comparable to 
parental DTA-1 rat IgG2b (Fig. 2, A and B). All versions of 
DTA-1 showed a similar ability to induce NF-B signaling in 
a reporter cell assay (Fig. 2 C). Moreover, the three DTA-1 vari-
ants similarly enhanced anti-CD3–mediated T cell proliferation 
Figure 1.  Activating, rather than inhibitory, FcRs are necessary 
for the antitumor activity of an agonistic antibody to GITR. Efficacy 
study of anti-GITR antibody (DTA-1 rIgG2b; 5 mg/kg i.p.) in wild type  
(A), FcRIIB/ (B), and Fc common  chain/ (C) BALB/c mice bearing 
Colon26 tumors (n = 6–10 mice per treatment group). Day 0 refers to 
treatment day, 6–8 d after tumor inoculation. Data is a representative of 
two or more independent experiments.JEM Vol. 210, No. 9  1687
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Figure 2.  Engagement of FcRs by DTA-1 is required for antitumor activity. (A and B) GITR-binding assay. Primary splenocytes stimulated with 
CD3- and CD28-specific antibodies served as targets. DTA-1 variants were detected using rat IgG2b-specific (A) or murine IgG2a-specific (B) PE-conjugated 
antibodies. (C and D) In vitro activity of GITR-specific antibodies at various concentrations tested on GITR-expressing NF-kB 293 reporter cell line (C)  
and splenocytes incubated with suboptimal doses of anti-CD3 and anti-CD28 antibodies (D). The in vitro data are derived from triplicates and are a  1688 Immunomodulatory antibodies and FcRs | Bulliard et al.
showing an obvious shift in the ratio of CD8+ T cells to T reg 
cells in the tumor, although in the previous reports, tumors 
were extracted at later time points after the onset of regres-
sion (Ko et al., 2005; Sharma et al., 2008; Cohen et al., 2010). 
Importantly, DTA-1 treatment did not affect the overall den-
sity of tumor-associated leukocytes, supporting that T cell 
elimination was a specific event (Fig. 3 H). Again, the cellular-
ity of T cells in the tumor-draining lymph node, as well as the 
ratio of CD8+ T cells to T reg cells, remained mostly un-
changed (Fig. 3 I and not depicted). Together, our data reveal 
that DTA-1–mediated an FcR-dependent loss of T cells in 
the tumor, with the magnitude of depletion correlating with 
cell surface expression of GITR (T reg→FoxP3-CD4+→CD8+). 
Furthermore, we demonstrate that the loss of intratumoral   
T cells precedes tumor regression, supporting that this deple-
tion mechanism may serve as an initial event that culminates 
in tumor rejection.
Activating, but not inhibitory, FcRs are required  
for intratumoral T reg cell depletion
To evaluate if the depletion of intratumoral T cells required 
activating FcR expression, we monitored T cell populations 
in wild-type, FcRIIB-, and Fc common  chain–deficient mice 
after treatment with DTA-1-mIgG2a. Murine IgG2a DTA-1 
mediated potent T reg and non–T reg cell elimination in both 
wild-type and FcRIIB-deficient animals, which resulted in 
a shift in the ratio of CD8+ T cells to T reg cells in the tumor, 
whereas the ratio remained unchanged in the draining lymph 
node (Fig. 4, A and B). In contrast, no significant depletion or 
shift in T cell ratio was observed in mice devoid of activating 
FcR expression (Fig. 4 C). GITR expression on T cell pop-
ulations isolated from tumors and lymph nodes was conserved 
between the three strains and was highest among intratumoral 
T reg cells (Fig. 4, D and F). These data support the notion 
that  treatment  with  antibodies  targeting  GITR-expressing 
tumor-infiltrating T cells leads to activatory FcR-dependent 
elimination, the degree of which correlates with levels of 
GITR expression.
Activating FcRs are also required for the antitumor activities 
of an antibody targeting the non-TNFR antigen CTLA-4
With the unexpected dependence on activatory FcRs for 
DTA-1–mediated antitumor activity, we next sought to un-
derstand if this finding was restricted to a T cell–expressed 
immunostimulatory TNFRs. To evaluate this, we chose an   
antagonist antibody (clone 9D9, murine IgG2b) targeting 
the T cell antigen CTLA-4, which functions to negatively 
regulate T cell proliferation upon signaling (Leach et al., 1996; 
Curran et al., 2010). Consistent with earlier reports, a single 
of these variants (Fig. 2 G). Collectively, our results support 
that agonist antibodies targeting GITR require co-engagement 
with activating FcRs for their tumoricidal activities in 
this model.
Co-engagement of FcRs by DTA-1 results  
in intratumoral loss of T cells
To  further  understand  the  underlying  FcR-dependent 
mechanism of DTA-1, we analyzed the immune cell popula-
tions in tumor and draining lymph node after administration 
of  the  DTA-1  variant  antibodies,  focusing  on  early  time 
points before tumors typically begin to regress. First, we con-
firmed that GITR was expressed on T cells in the draining 
lymph node and tumor (Fig. 3 A; Shimizu et al., 2002). The 
highest expression of GITR was by T cells in the tumor com-
pared with the draining lymph node, with T reg cells in the 
tumor showing approximately fourfold stronger signal than 
the  equivalent  lymph  node  population.  Next,  we  profiled   
myeloid  and  NK  cells  for  expression  of  FcRIII  and  IV   
(Fig. 3, B and C). Tumor-associated myeloid and NK cell 
populations were abundant in Colon26 tumors (>50% of all 
CD45+ leukocytes) and expressed activating FcRIII/FcRIV 
and FcRIII, respectively. FcRIII was distinguished from 
FcRIIB using mice deficient for FcRIIB in combination 
with the 2.4G2 antibody, which cross-reacts with FcRIIB 
and III. In contrast, the same innate immune cell populations 
were underrepresented in the tumor-draining lymph node 
(<0.5% of all leucocytes; Fig. 3 B). Treatment with the paren-
tal or mIgG2a DTA-1 variant resulted in a strong reduction 
in the percentage of intratumoral FoxP3+ T reg cells (Fig. 3 D). 
This effect was specific to the tumor, with no significant change 
in the T reg cell population in draining lymph nodes. In con-
trast, treatment with the DTA-1-N297A variant did not alter 
intratumoral T cell populations, supporting dependence on 
FcR interactions for this effect. To quantify the change in   
T cell populations after DTA-1 variant treatment, we moni-
tored the density of T cells in the tumor over 5 d. By 24 h, the 
parental rat IgG2b or DTA-1 mIgG2a mediated a dramatic 
reduction in the density of FoxP3+ T reg cells in the tumor, 
which did not occur in the DTA-1-N297A–treated cohort 
(Fig. 3 E). Although the loss of intratumoral T cells was most 
dramatic at early time points in the T reg cell population, 
CD4+ T cells were also significantly reduced on days 3 and   
5 after antibody treatment (Fig. 3 F). A slight reduction in the 
density of CD8+ T cells was also observed, particularly in the 
DTA-1 mIgG2a cohort. The depletion of T reg cells was most 
pronounced, which resulted in a significant shift in the ratio 
of CD8+ T cells to T reg cells in the tumor early after treat-
ment (Fig. 3 G). This finding correlated with previous reports 
representative of two or more independent experiments. (E) Efficacy study of 5 mg/kg DTA-1 mIgG2a in wild-type, FcRIIB/, and Fc common  chain/ 
mice bearing Colon26 tumors (n = 7–10 mice per treatment group). Mean and standard errors are based on triplicates, and the data is a representative  
of two or more independent experiments. (F) In vivo efficacy study after treatment with the DTA-1 variant antibodies (n = 7). The efficacy data are a  
representative of two or more independent experiments. (G) Saturation of GITR on T reg cells in the tumor and draining lymph node by the three  
versions of DTA-1.
 JEM Vol. 210, No. 9  1689
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Figure 3.  Engagement of FcRs by DTA-1 induces loss of intratumoral T reg cells early after treatment. (A) Cell surface expression of GITR on 
day 0 (n = 3). (B and C) Dot plots of CD11b+ myeloid and DX5+ NK cells, gated on live CD45+ leukocytes (B) and expression of FcRII/III and IV by the two 
cell populations in the tumor (C). (D) Dot plots of T cells 3 d after treatment with the DTA-1 variant antibodies. Percentages of live CD45+ CD3+ T cells are 
indicated. The data are a representative of two or more independent experiments. (E and F) Density of T reg cells (E) and FoxP3-CD4+ T cells and CD8+  
T cells (F) in the tumor after treatment with the 5 mg/kg DTA-1 variants. (G) Ratio between CD8+ T cells and T reg cells in the tumor. (H) Percentage of 
intratumoral CD45+ leukocytes. (I) T cell number in the draining lymph nodes after treatment with 5 mg/kg of the DTA-1 variants. Mean and standard 
errors are based on triplicates from two independent experiments. P-values were calculated using an unpaired Student’s t test (**, P < 0.001).
intraperitoneal injection of 9D9 mediated tumor regressions 
in 100% of animals (Fig. 5 A; Leach et al., 1996; Curran et al., 
2010). To explore the involvement of FcR in anti–CTLA-4–
mediated antitumor efficacy, we evaluated tumoricidal activity 
of anti-CTLA4 in mice devoid of activating FcR expression 
(Fig. 5 A). Similar to what we observed in DTA-1–treated   
animals, 9D9 efficacy was strictly dependent on activating FcRs. 
Similar to the expression profile of GITR, CTLA-4 was ex-
pressed by intratumoral CD4+ T cells, most notable the T reg 
cell population (Fig. 5 B). 9D9 administration resulted in the 1690 Immunomodulatory antibodies and FcRs | Bulliard et al.
with anti–CTLA-4 treatment this observation was less clear 
with an overall reduction of intratumoral CD4+ T cells on 
day 5. We reconcile these observations with the ability of acti-
vatory FcR-expressing immune effector cells to elicit ADCC, 
based on a receptor threshold model (Lewis et al., 1993; Niwa 
et al., 2005). In contrast, few myeloid or NK cells were pres-
ent in the draining lymph nodes, and the expression of GITR 
and CTLA-4 on FoxP3+ T reg cells in this compartment was 
lower than in the tumor. An alternative hypothesis is that   
agonist GITR signaling mediated by DTA-1 could alter the 
stability of the transcription factor FoxP3 expressed by intra-
tumoral T reg cells (Cohen et al., 2010). However, the loss of 
FoxP3-negative CD4+ T cells from DTA-1–treated and anti–
CTLA-4–treated tumors indicates that this FcR-dependent 
depletion mechanism may rather correlate with target antigen 
expression. Collectively, our data support a common mecha-
nism shared between antibodies targeting receptors highly 
expressed on intratumoral T reg cells and CD4+ T cells, at 
least in the Colon26 colorectal cancer model. Additional stud-
ies are required, however, to address whether these findings 
may be translatable to other less immunogenic tumor models. 
In addition, further studies will be required to establish the 
specific depletion of tumor-associated T cells and a shift in the 
ratio of CD8+ to T reg cells, which was dependent on activating 
FcR expression (Fig. 5 C). Together, these data support a com-
mon antitumor mechanism shared between antibodies targeting 
receptors highly expressed at the surface of intratumoral CD4+   
T cells, which requires the function of activating FcRs.
Here, we have shown that antibodies targeting two func-
tionally distinct immunoregulatory receptors on T cells re-
quire the coengagement of activatory FcRs to mediate their 
antitumor effect. A single dose of the GITR targeting anti-
body DTA-1 mediated the rapid and selective elimination of 
T cells within the tumor microenvironment, particularly those 
of the T reg cell lineage, as defined by intracellular FoxP3 ex-
pression. The dependence on the expression of activating FcRs 
for T cell depletion appears consistent with involvement of 
the immune effector cell mechanisms ADCC or ADCP. In-
deed, tumor-associated immune effector cells expressing acti-
vating FcRIII and IV were abundant in Colon26 tumors 
and are known to mediate ADCC or ADCP effects in other 
model systems (Nimmerjahn and Ravetch, 2005; Albanesi et al., 
2012). In general, the depletion of T cell populations corre-
lated with the overall level of target antigen expression, although 
Figure 4.  Activating, but not inhibitory, FcRs are required for intratumoral T reg cell depletion by antibodies targeting GITR. Intratumoral  
T cell density and CD8+ T cells to T reg cells ratios 5 d after treatment with 5 mg/kg DTA-1-mIgG2a using wild-type (A), FcRIIB/ (B), or Fc common  
chain/ (C) mice bearing Colon26 tumors. (D–F) Cell surface expression of GITR on T cells. Mean and standard errors are based on triplicates from two 
independent experiments. P-values were calculated using an unpaired Student’s t test (**, P < 0.001).JEM Vol. 210, No. 9  1691
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be considered for clinical evaluation. In parallel, a prospective 
or retrospective study to analyze patients carrying the allelic 
variants of the activating FcRIIA and III could be valuable, 
particularly given the striking correlation with progression-
free survival in patients treated with Rituximab (Weng and 
Levy, 2003). In these settings, a challenge will be to design 
relevant preclinical models to evaluate the efficacy of immuno-
modulatory antibodies that better correlate clinical response, 
and our findings provide a framework to test this with future 
immunomodulatory antibodies. For instance, mice engineered 
to express the human FcR system might be of great utility 
(Smith et al., 2012).
MATERIALS AND METHODS
Mice and tumor models. 6–10-wk-old wild-type BALB/c female mice 
were obtained from Charles River Laboratory or Taconic and aged-matched 
BALB/c  FcRIIB/  and  Fc  common    chain/  female  mice  from   
Taconic. The BALB/c-derived colorectal carcinoma cell line Colon26 was 
obtained from the DCTD Tumor Repository, National Cancer Institute, 
Frederick, MA. Colon26 cells were maintained at subconfluent density and 
under low number of passages before being inoculated, typically by subcuta-
neous injection of 5 × 105 cells onto the right flank of BALB/c mice. Tumor 
diameter was measured by electronic caliper every 2–3 d, and tumor volume 
was determined by length × width2/2. For all experiments, mice were housed 
at  the  Novartis  Cambridge  Laboratory Animal  Services. All  procedures   
were performed in accordance with the standards of the US Department   
of Health and Human Services and were approved by the Novartis Animal 
Welfare Committee.
Antibody production and treatment. The parental rat IgG2b DTA-1–
producing hybridoma was provided by S. Sakaguchi (Immunology Frontier 
Research Center, Osaka University, Osaka, Japan). The variable region 
exact mechanism of T cell depletion, to understand how de-
pletion of T reg cell and non–T reg cell populations augment 
subsequent adaptive antitumor immune response, and, finally, 
to further explore how antibody-mediated GITR forward 
signaling contributes to antitumor immunity.
The requirement for activating FcR coengagement for 
antibodies targeting costimulatory and inhibitory cell surface 
targets within the T cell–APC interface supports the possibil-
ity of using antibody engineering to enhance their therapeu-
tic activity. This conclusion draws parallels with recent efforts 
to augment activating FcR coengagement of antibodies   
targeting tumor associated targets, such as HER2 or CD317 
(Junttila et al., 2010; Nordstrom et al., 2011; Tai et al., 2012). 
Interestingly,  ipilimumab,  an  antagonist  antibody  targeting 
CTLA-4 with human IgG1 framework, has shown efficacy in 
metastatic melanoma patients. Human IgG1 antibodies have 
an intrinsically higher activating to inhibitory (A/I) FcR 
ratio, which is proposed to favor ADCC effector mecha-
nisms (Hodi et al., 2010; Robert et al., 2011; Hogarth and   
Pietersz, 2012). In contrast, another antagonist antibody tar-
geting CTLA-4, tremelimumab, is a human IgG2 antibody 
and has a lower A/I ratio. This antibody failed to reach its 
endpoints in a clinical trial (Chung et al., 2010). Although 
these two antibodies remain to be compared directly in pa-
tients, it is tempting to speculate that the varying ability of 
IgG1 versus IgG2 to bind human activating FcRs may explain, 
at least in part, the apparent difference in clinical response. 
Accordingly,  Fc-optimized  variants  of  ipilimumab,  such  as 
mutations designed to enhance ADCC or ADCP, could also 
Figure 5.  Engagement of activating FcRs is also required for the antitumor activity of an antibody targeting the non-TNFR CTLA-4.  
(A) Efficacy study using 15 mg/kg CTLA-4–specific antibody (9D9) in wild-type (top) or Fc common  chain/ (middle) mice bearing Colon26 tumors 
(n = 8–10 mice per treatment group). (B) Intratumoral T cell density and CD8+ to T reg cells ratios 5 d after treatment. (C) Cell surface expression of CTLA-4 on 
T cells. The efficacy data are a representative of two or more independent experiments. Mean and standard errors are based on triplicates from two inde-
pendent experiments. P-values were calculated using an unpaired Student’s t test (*, P < 0.01).1692 Immunomodulatory antibodies and FcRs | Bulliard et al.
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